Latest Insurance News

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.

Aeeris Ltd reported solid growth in Q2 FY25, driven by increased annual recurring revenue and new contracts across key sectors, while unveiling a promising new technology set to expand its market footprint.

Ramsay Health Care announces key leadership departures and a strategic realignment aimed at strengthening its core Australian hospital business and accelerating transformation under CEO Natalie Davis.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.

Prominence Energy reports steady progress in its uranium and gas exploration projects while pursuing new growth opportunities focused on capital efficiency and operational flexibility.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

Vital Metals reports a substantial 56% increase in Measured and Indicated Resources at its Tardiff project, alongside a significant expansion of its Nechalacho land footprint and plans for a forthcoming Scoping Study.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

FINEOS Corporation Holdings PLC reported a seasonal decline in cash balance and customer receipts in Q4 2024, while successfully onboarding new clients and maintaining a robust North American pipeline.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Foresta Group Holdings has raised $3.1 million through a convertible note and share placement, while securing exclusive technology licensing and key offtake agreements to propel its flagship New Zealand biomass project.